DICE Therapeutics

DICE Therapeutics

  • Founded: 2013
  • Location: South SF, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Psoriasis, immune-mediated conditions
  • Drug types: IMM, DRM, GI, ONC
  • Lead product: DC-806
  • Product link: https://www.dicetherapeutics.com/pipeline/
  • Funding: $345M stock Oct 2022; $204M IPO Sep 2021; $60M C-1 Aug 2021; $80M C Jan 2021



job board

Short description:

Small molecule compounds that act by unlocking protein-protein interfaces

Drug notes:

DC-853 Clin0 psoriasis, immune-mediated conditions; 5 undisclosed programs RD psoriasis, immune-mediated conditions, IBD, fibrosis, immuno-oncology, undisclosed

Long description:

DICE Therapeutics is discovering novel small molecules that can be used to treat various inflammatory diseases. Many current medicines to treat inflammatory diseases are not suited for chronic treatment as they would require regular patient monitoring and administration through injections or intravenous infusions. DICE is using their DELSCAPE platform to identify oral small molecules that modulate the binding of an inflammatory cytokine to its receptor as effectively as systemic biologics. Their growing pipeline of oral therapeutic candidates includes their lead program, DC-806 , that targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com